| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronary Stenosis | 16 | 2019 | 36 | 4.930 |
Why?
|
| Fractional Flow Reserve, Myocardial | 16 | 2018 | 23 | 4.590 |
Why?
|
| Graft Occlusion, Vascular | 15 | 2014 | 16 | 4.530 |
Why?
|
| Pulmonary Embolism | 6 | 2023 | 30 | 4.260 |
Why?
|
| Saphenous Vein | 17 | 2014 | 23 | 4.140 |
Why?
|
| Coronary Artery Bypass | 17 | 2023 | 43 | 4.140 |
Why?
|
| Takotsubo Cardiomyopathy | 11 | 2020 | 12 | 4.090 |
Why?
|
| Myocardial Infarction | 21 | 2023 | 221 | 3.910 |
Why?
|
| Coronary Occlusion | 8 | 2013 | 9 | 3.610 |
Why?
|
| Stents | 25 | 2020 | 59 | 3.560 |
Why?
|
| Coronary Angiography | 33 | 2021 | 92 | 3.160 |
Why?
|
| Treatment Outcome | 44 | 2023 | 1349 | 2.940 |
Why?
|
| Thrombectomy | 7 | 2023 | 12 | 2.440 |
Why?
|
| Hospitalization | 13 | 2022 | 370 | 2.420 |
Why?
|
| Drug-Eluting Stents | 17 | 2019 | 31 | 2.280 |
Why?
|
| Stroke | 7 | 2023 | 274 | 2.130 |
Why?
|
| Coronary Vessels | 6 | 2013 | 93 | 2.100 |
Why?
|
| Aortic Valve Stenosis | 6 | 2019 | 23 | 2.090 |
Why?
|
| Inpatients | 9 | 2020 | 72 | 2.050 |
Why?
|
| Coronary Artery Disease | 10 | 2019 | 147 | 2.010 |
Why?
|
| Humans | 120 | 2023 | 34853 | 1.930 |
Why?
|
| Heart Arrest | 5 | 2023 | 32 | 1.900 |
Why?
|
| Thrombolytic Therapy | 6 | 2023 | 17 | 1.900 |
Why?
|
| Aortic Valve | 5 | 2021 | 25 | 1.830 |
Why?
|
| Male | 81 | 2023 | 18870 | 1.810 |
Why?
|
| Middle Aged | 58 | 2023 | 9642 | 1.740 |
Why?
|
| Sepsis | 4 | 2019 | 76 | 1.670 |
Why?
|
| Ultrasonography, Interventional | 10 | 2023 | 16 | 1.630 |
Why?
|
| Hospital Mortality | 12 | 2022 | 183 | 1.620 |
Why?
|
| Atrial Fibrillation | 4 | 2020 | 105 | 1.620 |
Why?
|
| Cannabis | 4 | 2022 | 75 | 1.560 |
Why?
|
| Coronary Restenosis | 10 | 2012 | 26 | 1.410 |
Why?
|
| Aged | 46 | 2021 | 6448 | 1.370 |
Why?
|
| Heart Valve Prosthesis | 3 | 2013 | 17 | 1.340 |
Why?
|
| United States | 30 | 2023 | 3894 | 1.220 |
Why?
|
| Female | 51 | 2023 | 19873 | 1.160 |
Why?
|
| Acute Coronary Syndrome | 5 | 2021 | 35 | 1.150 |
Why?
|
| Thrombosis | 7 | 2013 | 61 | 1.140 |
Why?
|
| Hypertension | 4 | 2022 | 770 | 1.060 |
Why?
|
| Hemodynamics | 6 | 2020 | 86 | 1.030 |
Why?
|
| Embolectomy | 2 | 2020 | 2 | 0.980 |
Why?
|
| Collateral Circulation | 6 | 2014 | 10 | 0.980 |
Why?
|
| Propensity Score | 4 | 2019 | 40 | 0.920 |
Why?
|
| Young Adult | 17 | 2023 | 4012 | 0.910 |
Why?
|
| Obesity | 3 | 2020 | 965 | 0.900 |
Why?
|
| Mood Disorders | 3 | 2020 | 43 | 0.900 |
Why?
|
| Dyslipidemias | 3 | 2020 | 42 | 0.890 |
Why?
|
| Coronary Disease | 4 | 2014 | 113 | 0.870 |
Why?
|
| Prevalence | 12 | 2020 | 1425 | 0.840 |
Why?
|
| Heart Failure | 3 | 2017 | 230 | 0.820 |
Why?
|
| Marijuana Abuse | 1 | 2022 | 83 | 0.810 |
Why?
|
| Anterior Wall Myocardial Infarction | 2 | 2012 | 2 | 0.810 |
Why?
|
| Databases, Factual | 8 | 2020 | 288 | 0.780 |
Why?
|
| Adult | 26 | 2023 | 11034 | 0.780 |
Why?
|
| Chronic Disease | 9 | 2014 | 469 | 0.760 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2020 | 13 | 0.760 |
Why?
|
| Retrospective Studies | 13 | 2023 | 1961 | 0.760 |
Why?
|
| Heart Transplantation | 2 | 2012 | 43 | 0.760 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 37 | 0.750 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2012 | 6 | 0.750 |
Why?
|
| Myocardial Ischemia | 3 | 2012 | 72 | 0.740 |
Why?
|
| Cocaine | 1 | 2022 | 219 | 0.740 |
Why?
|
| Adolescent | 14 | 2023 | 5035 | 0.720 |
Why?
|
| Diabetes Mellitus | 4 | 2020 | 465 | 0.710 |
Why?
|
| Coronary Thrombosis | 2 | 2012 | 6 | 0.710 |
Why?
|
| Mental Disorders | 2 | 2020 | 285 | 0.700 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 229 | 0.690 |
Why?
|
| Risk Factors | 19 | 2023 | 3414 | 0.680 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 2 | 2009 | 2 | 0.670 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 2333 | 0.670 |
Why?
|
| Electrocardiography | 5 | 2012 | 154 | 0.620 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2014 | 60 | 0.590 |
Why?
|
| Depression | 2 | 2019 | 664 | 0.550 |
Why?
|
| Atherectomy, Coronary | 3 | 2019 | 3 | 0.540 |
Why?
|
| Anxiety | 2 | 2019 | 705 | 0.530 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 685 | 0.530 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 206 | 0.530 |
Why?
|
| Smoking | 2 | 2020 | 903 | 0.530 |
Why?
|
| Heart Atria | 3 | 2020 | 27 | 0.520 |
Why?
|
| Adenosine | 2 | 2012 | 54 | 0.510 |
Why?
|
| Ventricular Function, Left | 2 | 2013 | 104 | 0.510 |
Why?
|
| Comorbidity | 7 | 2021 | 606 | 0.510 |
Why?
|
| Heart Ventricles | 3 | 2012 | 121 | 0.500 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2013 | 88 | 0.500 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2018 | 19 | 0.500 |
Why?
|
| Myocardium | 2 | 2013 | 224 | 0.490 |
Why?
|
| Postoperative Complications | 5 | 2019 | 206 | 0.480 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 608 | 0.480 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2011 | 64 | 0.480 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 20 | 0.470 |
Why?
|
| Tissue Donors | 1 | 2013 | 43 | 0.470 |
Why?
|
| Arteries | 1 | 2013 | 67 | 0.470 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 964 | 0.460 |
Why?
|
| Ventricular Septum | 1 | 2012 | 2 | 0.450 |
Why?
|
| Heart Neoplasms | 1 | 2012 | 7 | 0.440 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2013 | 34 | 0.440 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 13 | 0.440 |
Why?
|
| Sarcoidosis | 1 | 2012 | 11 | 0.440 |
Why?
|
| Registries | 3 | 2023 | 330 | 0.440 |
Why?
|
| Incidence | 8 | 2021 | 882 | 0.430 |
Why?
|
| Angina Pectoris, Variant | 1 | 2012 | 1 | 0.430 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 48 | 0.430 |
Why?
|
| Lymph Nodes | 1 | 2012 | 67 | 0.430 |
Why?
|
| Coronary Aneurysm | 1 | 2012 | 3 | 0.430 |
Why?
|
| Graft Rejection | 1 | 2012 | 38 | 0.430 |
Why?
|
| Embolism, Cholesterol | 1 | 2011 | 1 | 0.430 |
Why?
|
| Mammary Arteries | 1 | 2011 | 3 | 0.430 |
Why?
|
| Time Factors | 12 | 2019 | 1681 | 0.420 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2011 | 11 | 0.420 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2012 | 23 | 0.420 |
Why?
|
| Catheterization | 1 | 2011 | 23 | 0.420 |
Why?
|
| Cardiomyopathies | 1 | 2012 | 55 | 0.410 |
Why?
|
| Disease Progression | 3 | 2017 | 580 | 0.410 |
Why?
|
| Decision Making | 1 | 2013 | 189 | 0.410 |
Why?
|
| Coronary Sinus | 1 | 2010 | 1 | 0.390 |
Why?
|
| Arteriovenous Fistula | 1 | 2010 | 14 | 0.390 |
Why?
|
| Anticoagulants | 2 | 2023 | 97 | 0.390 |
Why?
|
| Heart Septum | 1 | 2010 | 6 | 0.380 |
Why?
|
| Anastomosis, Surgical | 1 | 2010 | 22 | 0.370 |
Why?
|
| Myasthenia Gravis | 2 | 2020 | 4 | 0.370 |
Why?
|
| Carotid Stenosis | 2 | 2020 | 13 | 0.370 |
Why?
|
| Anaphylaxis | 2 | 2020 | 14 | 0.370 |
Why?
|
| Cardiotonic Agents | 1 | 2010 | 35 | 0.370 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 42 | 0.360 |
Why?
|
| Survival Rate | 5 | 2019 | 310 | 0.350 |
Why?
|
| Shock, Cardiogenic | 4 | 2023 | 9 | 0.350 |
Why?
|
| Prosthesis Design | 7 | 2014 | 26 | 0.350 |
Why?
|
| Paclitaxel | 6 | 2011 | 48 | 0.350 |
Why?
|
| Aorta | 1 | 2010 | 161 | 0.350 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2020 | 33 | 0.340 |
Why?
|
| Echocardiography | 4 | 2021 | 144 | 0.340 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 63 | 0.340 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 70 | 0.330 |
Why?
|
| Fibrinolytic Agents | 2 | 2021 | 23 | 0.320 |
Why?
|
| Neoplasms | 2 | 2018 | 1033 | 0.320 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2016 | 77 | 0.300 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 628 | 0.280 |
Why?
|
| Ephedra | 1 | 2005 | 1 | 0.260 |
Why?
|
| Heart Defects, Congenital | 2 | 2020 | 61 | 0.260 |
Why?
|
| Plant Preparations | 1 | 2005 | 21 | 0.260 |
Why?
|
| Risk Assessment | 6 | 2019 | 727 | 0.260 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1056 | 0.250 |
Why?
|
| Acute Disease | 2 | 2021 | 141 | 0.240 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2023 | 19 | 0.230 |
Why?
|
| Tricuspid Atresia | 1 | 2003 | 1 | 0.230 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2023 | 20 | 0.230 |
Why?
|
| Carotid Artery, Internal | 2 | 2020 | 6 | 0.230 |
Why?
|
| Postoperative Hemorrhage | 1 | 2023 | 14 | 0.230 |
Why?
|
| Metals | 4 | 2011 | 95 | 0.230 |
Why?
|
| Benzocaine | 1 | 2003 | 1 | 0.230 |
Why?
|
| Methemoglobinemia | 1 | 2003 | 2 | 0.230 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2003 | 19 | 0.230 |
Why?
|
| Anesthetics, Local | 1 | 2003 | 21 | 0.230 |
Why?
|
| Dietary Supplements | 1 | 2005 | 196 | 0.230 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2003 | 46 | 0.230 |
Why?
|
| Cardiomegaly | 1 | 2003 | 39 | 0.220 |
Why?
|
| Hemorrhage | 2 | 2013 | 46 | 0.220 |
Why?
|
| Cohort Studies | 4 | 2019 | 1422 | 0.220 |
Why?
|
| Atherosclerosis | 2 | 2016 | 131 | 0.220 |
Why?
|
| Tomography, Optical Coherence | 2 | 2012 | 42 | 0.220 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2023 | 76 | 0.220 |
Why?
|
| Cost of Illness | 2 | 2019 | 79 | 0.210 |
Why?
|
| Psychotic Disorders | 2 | 2020 | 52 | 0.210 |
Why?
|
| Equipment Design | 2 | 2013 | 127 | 0.210 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 211 | 0.210 |
Why?
|
| Myxoma | 1 | 2021 | 5 | 0.210 |
Why?
|
| Length of Stay | 2 | 2020 | 184 | 0.200 |
Why?
|
| Weather | 1 | 2021 | 7 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 592 | 0.200 |
Why?
|
| Retreatment | 3 | 2012 | 8 | 0.200 |
Why?
|
| Calcinosis | 1 | 2021 | 56 | 0.200 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 48 | 0.200 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 1 | 0.200 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 16 | 0.190 |
Why?
|
| Shock | 1 | 2020 | 2 | 0.190 |
Why?
|
| Takayasu Arteritis | 1 | 2020 | 1 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 14 | 0.190 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 6 | 0.190 |
Why?
|
| Prediabetic State | 1 | 2021 | 51 | 0.190 |
Why?
|
| Antithrombins | 1 | 2020 | 3 | 0.190 |
Why?
|
| Sex Factors | 2 | 2020 | 859 | 0.190 |
Why?
|
| Heparin | 1 | 2020 | 34 | 0.180 |
Why?
|
| Health Resources | 1 | 2020 | 32 | 0.180 |
Why?
|
| Hospitals | 1 | 2020 | 86 | 0.180 |
Why?
|
| Age Factors | 2 | 2020 | 1007 | 0.180 |
Why?
|
| Patient Admission | 1 | 2019 | 40 | 0.180 |
Why?
|
| Angiodysplasia | 1 | 2019 | 3 | 0.170 |
Why?
|
| Epilepsy | 1 | 2019 | 41 | 0.170 |
Why?
|
| Logistic Models | 3 | 2016 | 894 | 0.170 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 26 | 0.170 |
Why?
|
| Age Distribution | 1 | 2019 | 223 | 0.170 |
Why?
|
| Sex Distribution | 1 | 2019 | 212 | 0.160 |
Why?
|
| Alcoholism | 1 | 2021 | 220 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 47 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2023 | 1353 | 0.160 |
Why?
|
| Survivors | 1 | 2019 | 126 | 0.160 |
Why?
|
| Indians, North American | 1 | 2020 | 145 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2020 | 298 | 0.160 |
Why?
|
| Brain Ischemia | 1 | 2019 | 179 | 0.160 |
Why?
|
| Digoxin | 1 | 2017 | 6 | 0.150 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2017 | 11 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2018 | 82 | 0.150 |
Why?
|
| Child, Preschool | 2 | 2012 | 1318 | 0.140 |
Why?
|
| Angina, Unstable | 2 | 2012 | 8 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2018 | 775 | 0.140 |
Why?
|
| Medicaid | 1 | 2017 | 102 | 0.140 |
Why?
|
| Angiography | 2 | 2012 | 15 | 0.140 |
Why?
|
| Recurrence | 3 | 2011 | 125 | 0.140 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 8 | 0.120 |
Why?
|
| Cardiovascular Agents | 2 | 2011 | 20 | 0.120 |
Why?
|
| Critical Illness | 1 | 2014 | 37 | 0.120 |
Why?
|
| Diabetes Complications | 2 | 2011 | 91 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 10 | 0.110 |
Why?
|
| Child | 2 | 2012 | 2875 | 0.110 |
Why?
|
| Syncope | 1 | 2012 | 3 | 0.110 |
Why?
|
| Mediastinum | 1 | 2012 | 5 | 0.110 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 4 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 11 | 0.110 |
Why?
|
| Drug Eruptions | 1 | 2012 | 8 | 0.110 |
Why?
|
| Tachycardia, Ventricular | 1 | 2012 | 11 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2011 | 107 | 0.110 |
Why?
|
| Webcasts as Topic | 1 | 2012 | 2 | 0.110 |
Why?
|
| Safety Management | 1 | 2012 | 14 | 0.110 |
Why?
|
| Thiophenes | 1 | 2012 | 31 | 0.110 |
Why?
|
| Tissue Survival | 1 | 2012 | 3 | 0.110 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 110 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 16 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2012 | 151 | 0.110 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2012 | 6 | 0.110 |
Why?
|
| Reoperation | 1 | 2011 | 22 | 0.110 |
Why?
|
| Consumer Health Information | 1 | 2012 | 22 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 233 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 54 | 0.100 |
Why?
|
| Diverticulum | 1 | 2011 | 2 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 446 | 0.100 |
Why?
|
| Piperazines | 1 | 2012 | 109 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2561 | 0.100 |
Why?
|
| Cause of Death | 3 | 2020 | 154 | 0.100 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2011 | 2 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2012 | 89 | 0.100 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 9 | 0.100 |
Why?
|
| Cannabinoids | 1 | 2012 | 54 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 756 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 61 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 35 | 0.100 |
Why?
|
| Embolism | 1 | 2010 | 1 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 424 | 0.100 |
Why?
|
| Patient Selection | 1 | 2012 | 154 | 0.100 |
Why?
|
| Vena Cava, Superior | 1 | 2010 | 4 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 9 | 0.100 |
Why?
|
| Nuclear Medicine | 1 | 2010 | 5 | 0.100 |
Why?
|
| Surgical Instruments | 1 | 2010 | 4 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 27 | 0.090 |
Why?
|
| Microspheres | 1 | 2010 | 45 | 0.090 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 16 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 50 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2009 | 333 | 0.090 |
Why?
|
| Aspirin | 1 | 2010 | 45 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2009 | 27 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 468 | 0.090 |
Why?
|
| Albuminuria | 2 | 2007 | 76 | 0.090 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2008 | 26 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2009 | 121 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 386 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 182 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 984 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 27 | 0.080 |
Why?
|
| Endothelium, Vascular | 4 | 2012 | 229 | 0.080 |
Why?
|
| Water | 1 | 2009 | 283 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2008 | 202 | 0.080 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 19 | 0.080 |
Why?
|
| Dyspnea | 1 | 2007 | 15 | 0.080 |
Why?
|
| Respiration | 1 | 2007 | 49 | 0.080 |
Why?
|
| Chest Pain | 1 | 2007 | 36 | 0.070 |
Why?
|
| Exercise Test | 1 | 2007 | 68 | 0.070 |
Why?
|
| Proteins | 1 | 2009 | 352 | 0.070 |
Why?
|
| Peptides | 1 | 2009 | 308 | 0.070 |
Why?
|
| Emergency Service, Hospital | 2 | 2007 | 188 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2006 | 31 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 213 | 0.070 |
Why?
|
| Fatigue | 1 | 2007 | 79 | 0.070 |
Why?
|
| Single-Blind Method | 3 | 2011 | 50 | 0.070 |
Why?
|
| Meditation | 1 | 2006 | 25 | 0.070 |
Why?
|
| Yoga | 1 | 2006 | 27 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 1003 | 0.070 |
Why?
|
| Infant | 1 | 2008 | 1014 | 0.070 |
Why?
|
| Total Quality Management | 1 | 2004 | 9 | 0.060 |
Why?
|
| Cardiology Service, Hospital | 1 | 2004 | 4 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 423 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2003 | 115 | 0.060 |
Why?
|
| Hospitals, Urban | 1 | 2022 | 38 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2006 | 541 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 570 | 0.050 |
Why?
|
| Precipitating Factors | 1 | 2020 | 2 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2020 | 9 | 0.050 |
Why?
|
| Hirudins | 1 | 2020 | 1 | 0.050 |
Why?
|
| Hospital Charges | 1 | 2020 | 13 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 50 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2020 | 22 | 0.050 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2019 | 8 | 0.050 |
Why?
|
| Home Care Services | 1 | 2020 | 29 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 37 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2020 | 92 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 196 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 72 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 150 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 152 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 485 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2020 | 166 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 138 | 0.040 |
Why?
|
| Recreation | 1 | 2018 | 29 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2019 | 231 | 0.040 |
Why?
|
| Drug Utilization Review | 1 | 2017 | 7 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 707 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 555 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 281 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 187 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2016 | 228 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 517 | 0.030 |
Why?
|
| Hyperemia | 1 | 2013 | 4 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2011 | 38 | 0.030 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2011 | 4 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 109 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 145 | 0.020 |
Why?
|
| Angiotensin II | 1 | 2011 | 92 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 204 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2010 | 52 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 407 | 0.020 |
Why?
|
| Greece | 1 | 2009 | 18 | 0.020 |
Why?
|
| Food Deprivation | 1 | 2009 | 30 | 0.020 |
Why?
|
| Ticlopidine | 1 | 2009 | 15 | 0.020 |
Why?
|
| Fasting | 1 | 2009 | 50 | 0.020 |
Why?
|
| Animals | 3 | 2011 | 14307 | 0.020 |
Why?
|
| Veterans | 1 | 2009 | 115 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2007 | 5 | 0.020 |
Why?
|
| Emergencies | 1 | 2007 | 23 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 18 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 577 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 87 | 0.020 |
Why?
|
| Forecasting | 1 | 2007 | 124 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2006 | 8 | 0.020 |
Why?
|
| Diabetic Retinopathy | 1 | 2007 | 65 | 0.020 |
Why?
|
| Vasodilation | 1 | 2006 | 65 | 0.020 |
Why?
|
| Sirolimus | 1 | 2006 | 58 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 72 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2006 | 59 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2011 | 874 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2006 | 147 | 0.020 |
Why?
|
| Heart Rate | 1 | 2006 | 248 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 195 | 0.020 |
Why?
|
| Lipids | 1 | 2006 | 222 | 0.020 |
Why?
|
| Connecticut | 1 | 2004 | 14 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2004 | 9 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2006 | 628 | 0.020 |
Why?
|
| Apoptosis | 1 | 2011 | 1317 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2004 | 316 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 613 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 5668 | 0.010 |
Why?
|